Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews

Oct 29 2018

• By Derrick Gingery

FDA Advisory Committee Feature image

Related Content

US FDA Appoints Another Orphan Products Development Office Head Amid Growth Expectations

Oct 15 2018

Advocates Press For US FDA Rare Disease Center Of Excellence

Sep 13 2018

Center Of Excellence Not Best Model For US FDA Rare Disease Program, Woodcock Says

Sep 13 2018

Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Jul 18 2016

US FDA May Change Advisory Committee Planning, Member Screening

Jan 23 2017

FDA Adds Temporary Expertise To ODAC For Filgrastim Biosimilar Meeting

Jan 05 2015

FDA DRUG ADVISORY COMMITTEES SHOULD NOT BE DISMANTLED, NDMA URGES

May 03 1993

US FDA's Rare Diseases Program Not Expected To Change With Drug Office Reorg

Jun 28 2018

Related Companies

Novartis AG

Amgen, Inc.

Additional Topics

United States Rare Diseases Advisory Committees FDA Regulation BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window